| __timestamp | Pharming Group N.V. | Teva Pharmaceutical Industries Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 4167274 | 9216000000 |
| Thursday, January 1, 2015 | 5247851 | 8296000000 |
| Friday, January 1, 2016 | 4925118 | 10044000000 |
| Sunday, January 1, 2017 | 14930297 | 11560000000 |
| Monday, January 1, 2018 | 25371768 | 10558000000 |
| Tuesday, January 1, 2019 | 23921274 | 9351000000 |
| Wednesday, January 1, 2020 | 25338236 | 8933000000 |
| Friday, January 1, 2021 | 20182966 | 8284000000 |
| Saturday, January 1, 2022 | 17562000 | 7952000000 |
| Sunday, January 1, 2023 | 25212000 | 8200000000 |
| Monday, January 1, 2024 | 8480000000 |
Unveiling the hidden dimensions of data
In the ever-evolving pharmaceutical industry, understanding cost dynamics is crucial. Teva Pharmaceutical Industries Limited and Pharming Group N.V. present a fascinating study in contrasts. From 2014 to 2023, Teva's cost of revenue has shown a gradual decline, dropping approximately 14% from its peak in 2017. This trend reflects Teva's strategic cost management amidst a challenging market landscape. Meanwhile, Pharming Group N.V. has experienced a dramatic rise, with costs increasing over 500% during the same period. This surge highlights Pharming's aggressive expansion and investment in new product lines. The data underscores the diverse strategies employed by these companies to navigate the competitive pharmaceutical sector. As Teva focuses on efficiency, Pharming bets on growth, offering a compelling narrative of adaptation and ambition in the face of industry challenges.
Eli Lilly and Company vs Pharming Group N.V.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Bristol-Myers Squibb Company vs Teva Pharmaceutical Industries Limited
Cost of Revenue: Key Insights for Regeneron Pharmaceuticals, Inc. and Pharming Group N.V.
Cost of Revenue: Key Insights for Teva Pharmaceutical Industries Limited and Lantheus Holdings, Inc.
Cost of Revenue Comparison: Teva Pharmaceutical Industries Limited vs Veracyte, Inc.
Analyzing Cost of Revenue: Teva Pharmaceutical Industries Limited and Amphastar Pharmaceuticals, Inc.
Cost Insights: Breaking Down Teva Pharmaceutical Industries Limited and Evotec SE's Expenses
Comparing Cost of Revenue Efficiency: Insmed Incorporated vs Pharming Group N.V.
Analyzing Cost of Revenue: Dr. Reddy's Laboratories Limited and Pharming Group N.V.
Analyzing Cost of Revenue: Catalent, Inc. and Pharming Group N.V.
Cost Insights: Breaking Down Pharming Group N.V. and Corcept Therapeutics Incorporated's Expenses
Cost Insights: Breaking Down Pharming Group N.V. and Iovance Biotherapeutics, Inc.'s Expenses